Company: NOTV
Filing Date: 2025-12-05
Form Type: 10-K
Source: 0001628280-25-055483
Chunk: 219

Company: Inotiv, Inc.
Filing Date: 2025-12-05
Form: 10-K
Item: Item 1
Chunk 219
---
 conduct. They further our knowledge of living systems and help in the discovery and development of products that can save or enhance human and animal lives. The Company works with the scientific community to improve our understanding and promote best practice in the care and welfare of research animals. As providers of research models to the research community and scientists conducting experiments on behalf of our clients to help discover and develop new medicines, Inotiv is responsible to our clients and the public for the health and well-being of the animals in our care. 

Further, the FDA Modernization Act 2.0, passed in December 2022, removed certain references to animal testing in the Federal Food, Drug and Cosmetic Act (the "FDCA") to facilitate the broader acceptance of alternatives to animal testing. In April 2025, the FDA published a roadmap to reduce animal testing in preclinical safety studies with scientifically validated new approach methodologies ("NAMs"). Inotiv supports, has invested in, and plans to continue to invest in, the use of NAMs toward the development of efficacious and safe therapies. Currently, some of the services we offer in support of NAMs include computational toxicology, genetic toxicology in bacteria and mammalian cells, and proteomic pathway profiling in human and animal tissues.

Human Capital Management

As of September 30, 2025, we had 1,945 full-time employees and 101 part-time employees. All employees enter into confidentiality agreements intended to protect our proprietary information. We believe that our relations with our 

12

employees are good. None of our employees are represented by a labor union. Our performance depends on our ability to attract and retain qualified professional, scientific and technical staff. The level of competition among employers for skilled personnel is high. We believe that our employee benefit plans enhance employee morale, professional commitment and work productivity and provide an incentive for employees to remain with the Company.

Our primary objectives and philosophy of our compensation programs are to (i) drive leadership behaviors that maximize long-term stockholder value creation and (ii) attract and retain talented colleagues with the skills necessary to successfully manage and grow our business. 

Attracting, retaining, and developing talent is a core principle of our talent management and total rewards strategy. Compensation and benefit programs are an important part of our employment relationship, which also includes challenging and rewarding work, growth and career development opportunities and being part of a leading CRO with a diverse and talented workforce that helps clients develop life-changing therapies. We strive to have the following features as part of our